An antibody-based biomarker discovery method by mass spectrometry sequencing of complementarity determining regions by Dekker, Lennard J. M. et al.
ORIGINAL PAPER
An antibody-based biomarker discovery method
by mass spectrometry sequencing
of complementarity determining regions
Lennard J. M. Dekker & Lona Zeneyedpour &
Eric Brouwer & Martijn M. van Duijn &
Peter A. E. Sillevis Smitt & Theo M. Luider
Received: 16 June 2010 /Revised: 8 October 2010 /Accepted: 19 October 2010 /Published online: 24 November 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract Autoantibodies are increasingly used as bio-
markers in the detection of autoimmune disorders and
cancer. Disease specific antibodies are generally detected
by their binding to specific antigens. As an alternative
approach, we propose to identify specific complementarity
determining regions (CDR) of IgG that relate to an
autoimmune disorder or cancer instead of the specific
antigen(s). In this manuscript, we tested the technical
feasibility to detect and identify CDRs of specific anti-
bodies by mass spectrometry. We used a commercial pooled
IgG preparation as well as purified serum IgG fractions that
were spiked with different amounts of a fully human
monoclonal antibody (adalimumab). These samples were
enzymatically digested and analyzed by nanoLC Orbitrap
mass spectrometry. In these samples, we were able to
identify peptides derived from the CDRs of adalimumab.
These peptides could be detected at an amount of 110
attomole, 5 orders of magnitude lower than the total IgG
concentration in these samples. Using higher energy
collision induced dissociation (HCD) fragmentation and
subsequent de novo sequencing, we could successfully
identify 50% of the detectable CDR peptides of adalimu-
mab. In addition, we demonstrated that an affinity purifi-
cation with anti-dinitrophenol (DNP) monoclonal antibody
enhanced anti-DNP derived CDR detection in a serum IgG
background. In conclusion, specific CDR peptides could be
detected and sequenced at relatively low levels (attomole-
femtomole range) which should allow the detection of
clinically relevant CDR peptides in patient samples.
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Introduction
Antibodies play an important role in many disorders,
including autoimmune diseases and cancer [1, 2]. Proteins
present in affected tissue of autoimmune diseases and
tumors can differ from proteins in normal tissue in quantity,
aminoacid sequence, structure or post-translational modifi-
cation. These changes can result in the production of
autoantibodies against disease-related proteins [3]. The
presence of specific autoantibodies in patients with auto-
immune diseases and cancer can be of interest for
diagnosis, prognosis [4, 5], drug targets [6]a n df o r
fundamental understanding of various disease processes.
In immune responses, activation of both T cells and B
cells directed against the (auto)antigen can occur. The B
cell activation (humoral response) will result in production
of antibodies against the (auto)antigen. In autoimmune
diseases, antibodies raised against (auto)antigens are pres-
ent in the blood at relatively high concentrations of μgs per
ml [7].
The genetic building blocks for antibodies are relatively
constant while the enormous variation is created by
recombination and somatic hypermutation that occur
especially in the complementarity determining regions
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antibody sequences occur during antibody maturation and
results in the selection of B-cell clones that produce the
antibodies with the highest affinity for the antigen. This
selection, in theory, may lead to a convergent development
of antigen binding regions, and antibodies with similar and
identical CDRs in different individuals despite the enor-
mous potential variation in antibodies [8–10]. In a recent
publication, the complete antibody repertoires of 14 zebra
fish were sequenced and compared at the mRNA level. The
antibody repertoires of these zebra fish showed significant-
ly more overlap than would be expected based on chance
alone, suggesting that the production of antibodies is not a
random process [11]. Our own research group investigated
antibodies from rats immunized with purified antigens.
Again, many similarities were found between samples from
a treatment group immunized with a particular antigen.
Based on these findings, we hypothesize that recurring
antibody CDRs are also present in human diseases such as
autoimmune diseases or cancer. The specific CDRs of these
antibodies may thus be used as biomarkers.
Conventional antigen based biomarker discovery techni-
ques have had only limited success in body fluids. The
huge dynamic range of protein concentrations, rapid
turnover and the fact that many proteins are not excreted
into the circulation probably contribute to this. The
technique described here approaches the problem from
another angle, in which instead of antigens, peptides from
the antibody are used as potential markers. The use of
antibodies has a number of advantages; antibodies are
excreted, present at high concentrations and purification or
enrichment of specific antibodies can be performed with a
number of well-established techniques [12, 13].We have
already shown that the analysis of enzymatic digests of
purified IgG fractions with advanced mass spectrometry
techniques can result in reproducible profiles of the
immunome [12].
In the current study, we will focus on the analytical
parameters related to the detection, quantification and
identification of CDRs peptides. We tested two different
approaches a non-targeted and an antigen targeted ap-
proach. For these experiments, the fully human monoclonal
antibody adalimumab and a murine monoclonal antibody
against dinitrophenol (DNP) were spiked into serum
samples and a commercial pooled IgG sample. Adalimu-
mab is an antibody which is used in the treatment of
rheumatoid arthritis. Adalimumab binds to tumor necrosis
factor alpha (TNFα), preventing it from activating TNF
receptors. Adalimumab can be obtained in relatively large
quantities and since the sequence of the antibody is known,
it is well-suited to optimize CDR identification by mass
spectrometry in a serum IgG background. In addition, we
determined whether an affinity-purification (targeted ap-
proach) of a monoclonal antibody could be used to improve
the sensitivity of detection of CDR peptides by mass
spectrometry compared to CDRs present in a crude serum
IgG background. Through such an approach, it may be
possible to improve the detection of those CDRs that are
responsible for affinity to particular disease related anti-
gens. To test the latter approach, we used a mouse
monoclonal antibody against the hapten dinitrophenol
(DNP). We selected a mouse monoclonal antibody in a
human antibody background to estimate non-specific
binding by means of aminoacid sequences of the constant
regions of mouse IgGs, which differ from corresponding
human sequences.
By conventional database searches, it is difficult to
comprehensively identify CDR peptides because the num-
ber of IgG sequences in publicly available protein databases
is relatively low. Identification of sequences that are not yet
present in a database requires high quality MS/MS data
for de novo sequencing. The quality of MS/MS data
usually depends on the amount and purity of the samples.
Since the amount of a serum sample is not a limiting
factor (ml of serum are routinely taken for diagnostic
purposes), samples can be extensively purified and
enriched for IgG. Interpretation of the MS/MS spectra
can be realized by specialized sequencing programs (both
database-dependent sequencing and de novo sequencing
as well as combinations thereof) [14–16]. We tested the
applicability of de novo sequencing for a number of CDR
peptides and used the higher energy collision induced
dissociation (HCD) fragmentation of the Orbitrap mass
spectrometer to obtain more accurate fragmentation
spectra for the de novo sequencing.
Method
Materials and reagents
Water, acetonitrile, formic acid and trifluoroacetic acid were
obtained from Biosolve, (Valkenswaard, The Netherlands).
Unless otherwise noted, all chemicals were purchased from
Sigma-Aldrich, (Saint Louis, MO).
Samples
In a commercial pooled IgG preparation (Nanogam,
Sanquin, Amsterdam, The Netherlands), we spiked five
different amounts of adalimumab (Humira, Abbott, Chi-
cago, IL): 0.0001, 0.001, 0.01, 0.1 and 1% (w/w adalimu-
mab / total IgG), corresponding to a final concentration of
0.001, 0.01, 0.1, 1 and 10 μg/ml of adalimumab,
respectively. We also included a negative control in which
no adalimumab was spiked. The sequence of adalimumab
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From five healthy volunteers, serum samples were
obtained via the Sanquin Blood Bank Rotterdam, the
Netherlands. The donors have given written consent for
the use of serum for research purposes according to general
guidelines of the Sanquin Blood Bank, Rotterdam. Imme-
diately after collection the serum samples were centrifuged,
aliquoted and stored at -80 °C. Three aliquots of each
sample were thawed, and two aliquots were spiked with 0.1
or 0.001% (w/w) of adalimumab / total IgG. For the
calculation of spiked amounts of adalimumab, a total IgG
concentration in serum of 13.5 g/l is taken as a standard
value [7].
IgG purification
IgG was purified from serum samples by Melon Gel
purification (Melon Gel IgG Purification Kit, Pierce,
Rockford, IL) according to the manufacturer’s protocol.
Briefly, serum samples were diluted 1:10 and the diluted
serum was added to a spin column containing the Melon
Gel resin. After 30 minutes incubation, the purified IgG
was collected in the flow through by centrifugation of the
spin column. All IgG purified samples were aliquoted and
stored at -20 °C.
In-solution digestion
To 10 μL of each sample, 10 μL 0.2% Rapigest (Waters
Corporation, Milford, MA), in 50 mM NH4HCO3 was
added. The solution was reduced with 10 mM dithiothreitol
(DTT) at 60 °C for 30 min. After the mixture was cooled
down to room temperature, it was alkylated in the dark with
50 mM iodoacetamide at ambient temperature for 30 min,
and digested overnight with 1:100 (w/w) trypsin (Promega,
Madison, WI). Five percent trifluoroacetic acid was added,
to obtain a final concentration of 0.5% trifluoroacetic acid
(pH<2). After 45 min of incubation at 37 °C the samples
were centrifuged at 13,000 g for 10 minutes.
Protein seperation SDS-PAGE
Using standard methods supplied by the manufacturer, one-
dimensional SDS-PAGE was performed. Ten percent poly-
acrylamide gels of 0.75 mm thickness were used. To each
sample 3 μL loading buffer was added and samples were
heated for 10 minutes at 90 °C. The gel was stained with
Novex® Colloidal Blue Staining (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. Subsequently,
gels were scanned and densitometry was performed on the
scan image using the ImageJ software package (http://rsb.
info.nih.gov/ij/)
In-Gel digestion
The gel bands were excised and cut into plugs. Plugs were
transferred into 1.5 mL Eppendorf tubes. The digestion was
performed in Rapigest detergent solution according to the
manufacturer’s instructions. Briefly, the cut gel plugs were
washed with water (10 min) and subsequently washed with
a mixture of water/acetonitrile (1 : 1, v/v; for 10 min). A
sufficient volume of water/acetonitrile was added to shrink
the gel plugs. The solution was removed and the gel plugs
were rehydrated with 100 mM NH4HCO3 for 5 min. An
equal volume of acetonitrile was added to the 100 mM
NH4HCO3 solution, and it was incubated for 15 min. The
washing solution was then removed and the gel plugs were
dried in a Speedvac (SPD 1010, Thermo Savant, Holbrook,
NY). The proteins were reduced with 10 mM DTT in
100 mM NH4HCO3 (45 min at 56 °C). After removing the
reducing solution, proteins were alkylated in the dark with
50 mM iodoacetamide in 100 mM NH4HCO3 (30 min).
The alkylation was stopped by removing the reaction
solution and by washing the gel plugs with a mixture of
water/acetonitrile (1 : 1, v/v), acetonitrile and acetonitrile/
100 mM NH4HCO3. After the gel plug were dried in a
Speedvac, 0.1% Rapigest in 50 mM NH4HCO3 was added
and incubated at 37 °C for 10 minutes. Subsequently, the
gel plugs were dried in a vacuum centrifuge. The gel plugs
were rehydrated at 4 °C (45 min) with 10 ng trypsin/μl
50 mM NH4HCO3. A sufficient volume of 50 mM
NH4HCO3 was added to completely cover the gel plugs.
The digestion was carried out overnight at 37 °C. Before
starting the extraction, the supernatant was transferred to an
Eppendorf tube. After adding to each sample 50 μL1 %
trifluoroacetic acid it was incubated at 65 °C for 2 minutes.
The supernatant was transferred into a new Eppendorf tube.
To the gel plugs, 50 μL 50% acetonitrile and 50 ul 0.1%
trifluoroacetic acid was added, the plugs were sonified for 2
minutes and subsequently incubated for 15 minutes at room
temperature. The three resulting supernatants were pooled
and dried in a vacuum centrifuge and redissolved in 50 μl
0.1% trifluoroacetic acid.
Affinity purification
Dot-blot
Amounts of 0.1 μg DNP BSA (US biological, Swampscott
MA) were spotted onto a methanol-wetted PVDF mem-
brane (0.5×20 mm
2). After blocking with BSA, the dot-
blots were washed in Tris-buffered saline (TBS) (200 mM
Tris, 1.5 M NaCl, 0.05% Tween-20 (v/v)). In the next step,
IgG containing samples were applied on top of the DNP-
BSA spots. The samples analyzed included 0.001, 0.01 and
0.1 μg of anti-DNP antibody (mouse monoclonal anti-DNP,
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human IgG samples (1 μg) spiked with two different
amounts of anti-DNP monoclonal 0.01, 0.1 μg and a
negative control containing only the purified human IgG.
The dot-blots were washed and incubated with alkaline
phosphatase labeled anti-mouse IgG (1:500) (Polyclonal
Rabbit anti-mouse IgG/AP, Dako, Glostrup, Denmark).
Subsequently, the dot-blots were washed again and binding
of antibodies was visualized by alkaline phosphatase
conjugate substrate kit (Biorad, Hercules, Canada).
Magnetic bead purification of specific antibodies for MS
analyses
DNP-BSA was coupled to magnetic beads (008Mag
PlexTM C, Luminex Corporation, Austin, TX). After
washing the beads with water, 160 μl 100 mM sodium
phosphate buffer pH 6.2, 20 μl 50 mg/mlN-hydroxysulfo-
succinimide, (Pierce, Rockford, IL), and 20 μl 50 mg/ml
carbodiimide EDC (Pierce, Rockford, IL) (the latter two
solutions both dissolved in water) were added. Subsequent-
ly, the beads were incubated at room temperature for 20
minutes. To the activated beads 930 μl 2-(N-morpholino)
ethanesulfonic acid (MES) pH 5.0 and 70 μl DNP-BSA
(2 mg/ml in water) was added, the beads were incubated for
2 hours at room temperature. Subsequently, the coupled
beads were blocked with PBS-TBN (PBS, 0.1% BSA,
0.02% Tween-20, 0.05% NaN3, pH 7.4) for 30 minutes at
room temperature. In the next step, beads were washed
twice with PBS-TBN. Finally, the beads were resuspended
in PBS-BN (PBS, 1% BSA, 0.05% NaN3, pH 7.4) and
stored at 4 °C until use.
Amounts of 0.5 μg, 1 μg and 2 μg of anti-DNP were
added to both 20 μl purified serum IgG and to 20 μlo f
PBS. Purified serum IgG without any spiked anti-DNP was
used as a negative control. These mixtures were added to
6.10
6 beads coupled with DNP-BSA and beads that were
not coupled to a protein. Subsequently, the beads were
washed three times with PBS-T (PBS, 0.05% Tween-20).
Before elution of the IgG from the beads, a fraction of each
sample 6.10
5 beads was conjugated with PE labeled anti-
mouse IgG (H+L) (Goat anti-mouse IgG (H+L), Caltag lab,
Buckingham, UK), as secondary antibody. Subsequently,
these fractions were measured and analyzed by the
Luminex® 100™ (Luminex cooperation, Austin, TX). The
remaining beads of each sample were incubated with 18 μl
of 100 mM Glycine-HCl, pH 2.9. Subsequently, 2 μlo f
1 M Tris-HCl, pH 9.0 was added to each sample to obtain a
final pH of 8. All samples were digested according to the
protocol described above (see section in-solution digest). In
addition to the eluted samples, the material loaded on the
beads was digested as well. Subsequently, all samples were
measured by nanoLC LTQ-Orbitrap MS. In Fig. 1,a
flowchart shows an overview of the different sample
preparation methods that were applied.
Mass spectrometry
The completion of the digestion step was checked with
reverse phase liquid chromatography and UV detection. For
nanoLC LTQ-Orbitrap mass spectrometry measurements,
five microliters (or higher volumes depending on the
intensity of the peptide signals in UV) of peptide sample
was injected on to a nanoliquid chromatography system
(nanoLC Ultimate 3000; Dionex, Sunnyvale, CA). After
preconcentration and washing of the sample on a C18 trap
column (1 mm×300 μm i.d.), peptides were separated on a
C18 PepMap column (250 mm×75 μm internal diameter)
(Dionex, Amsterdam) using a linear 90 min gradient (4-
40% acetonitrile/H20; 0.1% formic acid) at a flow rate of
300 nL/min. The separation of the peptides was monitored
by a UV detector (absorption at 214 nm). The nanoLC was
coupled to a nanospray source of a linear ion trap Orbitrap
(LTQ-Orbitrap) mass spectrometer (LTQ Orbitrap XL,
Thermo Electron, Bremen, Germany). All samples were
measured in a data dependent acquisition mode. Each run
was preceded by a blank MS run in order to monitor system
background. The peptide masses are measured in a survey
scan with a maximum resolution of 30,000 in the Orbitrap
and an AGC (automatic gain control) setting of 1.00×10
6.
To obtain a maximum mass accuracy, a prescan is used to
keep the ion population in the Orbitrap for each scan
approximately the same. During the high-resolution scan in
the Orbitrap, the 5 most intense monoisotopic peaks in the
spectra were fragmented and measured in the linear ion trap
with a normalized collision energy of 35% and an AGC
setting of 1.00×10
4. The fragment ion masses are measured
in the linear ion trap to have a maximum sensitivity and the
maximum amount of MS/MS data. For de novo sequencing,
we also measured samples with HCD fragmentation. By
this method the 3 most intense monoisotopic peaks in the
spectra were fragmented with both CID and HCD. The
HCD spectra were measured in the Orbitrap at a maximum
IgG samples spiked with
monoclonal
n o i t s e g i D Digestion Digestion light chain
SDS-PAGE separation Affinity purification
LC-Orbitrap measurement
Digestion
Fig. 1 Flow chart of the used sample preparation approaches
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of 40% and an AGC setting of 2.00e
5.
Data analyses
MS/MS spectra were extracted from raw data files and
converted into mgf files using Extract-MSN (part of
XCalibur version 2.0.7, Thermo Fisher Scientific Inc.).
Mascot (version 2.2.06; Matrix Science Inc., London, UK)
was used to perform database searches against the human
subset NCBInr database (version NCBInrHuman_data-
base_20090311; Homo sapiens species restriction; 222,071
sequences, to this database the sequence of adalimumab was
added) of the extracted MS/MS data. For the database
search the following settings were used: a maximum of
two miss cleavages, oxidation as a variable modification
of methionine, carbamidomethylation as a fixed modifica-
tion of cysteine and trypsin was set as enzyme. A peptide
mass tolerance of 10 ppm and a fragment mass tolerance
of 0.5 Da were allowed. An ion score of 40 was used as a
cut-off value.
In addition, the raw data files were also loaded into the
software package Progenesis LCMS (Version 2.5; Non-
lineair Dynamics Ltd, New Castle, UK). The data files were
aligned and feature selection was performed. Subsequently,
the results of the database search were loaded into
Progenesis. Finally, an export file was created in which
for each feature the abundances in the different samples are
displayed.
The IMGT website (http://imgt.cines.fr/3Dstructure-DB/
cgi/DomainGapAlign.cgi) is used to perform an alignment
of the adalumimab sequence to the closest germline
sequence.
de novo sequencing was performed using Peaks studio
5.1 (Bioinformatics Solutions Inc., Waterloo, Canada).
Orbitrap raw data files were loaded into Peaks and de novo
sequencing was performed. The parent peptide mass
accuracy was set at 10 ppm and for MS/MS fragments
obtained by CID 0.5 Da tolerance was allowed and 0.01 Da
for HCD data. For each spectrum maximal five de novo
sequences were proposed, the resulting sequences were
exported into a CSV file and the results were compared to
database dependent results.
Results
Characterization of adalimumab
The aminoacid sequence of adalimumab was largely
confirmed by nanoLC Orbitrap mass spectrometry analyses
using a shotgun approach. The sequence coverage was 91%
for the light chain and 83% for the heavy chain. The
obtained amino acid sequence of adalimumab was added to
the NCBInr database and the mass spectrometry data was
searched against this database using the Mascot search
engine. For this specific antibody the number of arginine
and lysine residues in and around the CDRs of the heavy
chain was relatively low, resulting in relatively large tryptic
fragments. Because these larger fragments could on average
be detected at a lower sensitivity, the CDR peptides derived
from the heavy chain had less intense MS signals than CDR
peptides from the light chain. For this reason, we focused
our analyses and measurements on the light chain of
adalimumab. All peptides identified in the light chain
CDR region are displayed in Table 1.
Spiking of adalimumab in IgG
We spiked a concentration range 0.0001%-1% w/w (11
attomole-110 femtomole absolute amounts analyzed) of
adalimumab in a commercial IgG pool (Nanogam) to
determine the lowest detectable concentration of the CDR
peptides in a complex IgG background. These spiked
samples were tryptically digested and analyzed by nanoLC
Orbitrap mass spectrometry. A combination of IgG peptides
derived from the constant regions was used for normaliza-
tion, although the influence of this normalization was
minimal. Four of the 11 CDR light chain peptides that
were identified during sequencing of adalimumab were also
detected in the spiked samples (see Table 2). The lowest
spiked concentrations at which specific CDR peptides
could be observed differed between the CDR peptides
(Table 2). The peptide LLIYAASTLQSGVPSR of the CDR
2 in the light chain was not specific and could also be
observed in the IgG pool without any spiked adalimumab.
This could be expected because this CDR did not contain
any mutation compared to IgG germline sequences (http://
imgt.cines.fr/3Dstructure-DB/cgi/DomainGapAlign.cgi).
The results of the alignment of the CDR peptides of the
light chain of adalimumab are displayed in Figure S1 of the
Electronic Supplementary Material. The linear dynamic
range of detection of spiked adalimumab is at least three
orders of magnitude for (R)NYLAWYQQKPGK(A) (mass
748.38822
2+ ) (Fig. 2). This experiment is performed in
duplicate which resulted in a similar linear dynamic range
as shown in the figure. The technical reproducibility of the
measurements is determined by running triplicate measure-
ments of the concentrations above the detection limit. This
resulted in an average CVof 18 % ranging from 10 – 22 %
for the normalized intensities of the peptide displayed in
Fig. 1. If the CV is calculated for all the measured peptides
an average CV is obtained of 27 %. More than 80 % of the
masses have a CV below 20 % which is comparable to the
results we obtained in a previous study in which we
investigated the reproducibility of Orbitrap measurements
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graphic traces of the sample spiked with 0.01% Adalimu-
mab are shown. In these chromatograms the complexity of
the sample and the intensity of the background in relation to
the peptides of interest can be observed. At this ratio of
0.01% (1.1 fmol adalimumab), MS/MS CID spectra can be
assigned to the correct CDR sequence by means of a
database dependent search.
Based on the above measurements in an artificial pool of
antibodies (Nanogam), two spiked concentrations (0.1% or
11 fmole yielded four detectable peptide peaks and 0.001%
or 110 attomole yielded one peptide peak, respectively)
were selected for studying the feasibility of sequencing
CDRs in IgG fractions from serum. Spiked percentages
were calculated based on an average IgG concentration in
serum of 13.5 mg/ml. The spiked samples were IgG
purified, tryptically digested and analyzed by nanoLC
Orbitrap mass spectrometry. During the data analyses we
focused on the three specific light chain’s CDR peptides of
adalimumab. In all samples the peptides could be detected
at a spiked ratio of 0.1%. At the ratio of 0.001% none of the
peptides could be detected. In addition, we separated the
spiked samples by SDS-PAGE (Fig. 4). Tryptic peptides
were extracted from the excised gel bands of the light chain
and measured by nanoLC-Orbitrap MS. In these samples,
all the CDR peptides displayed in Table 2 could be detected
at a 0.1% concentration level. The peptide (R)NYLA
WYQQKPGK(A) at mass 748.38822
2+ could be detected
in three out of the five samples at the 0.001% spiked
concentration. In addition, one sample was IgG purified by
Melon gel, analyzed on SDS-PAGE, tryptic digested and
subsequently measured by nanoLC-Orbitrap MS in tripli-
cate to determine the variation of the complete sample
preparation procedure. For these three measurements an
average CV of 29 % was obtained on the normalized
intensities of all MS signals.
In addition, we analyzed gels by densitometry to
determine the yield of IgG and its purity obtained by the
Melon Gel fractionation. On average the Melon Gel
purified IgG fractions contained 10.8 μg/μl of IgG as well
as 30-40% (w/w) of impurities. The commercial IgG pool
(Nanogam) contained 5-10% of impurities.
de novo sequencing of CDR peptides
An in-solution tryptic digest of 10 and 100 fmol/μl
adalimumab in buffer (equivalent to 1% and 0.1% spiked
concentration) was measured by nanoLC Orbitrap mass
spectrometry. In addition to the standard CID fragmentation
and detection in the LTQ, the peptides were also frag-
MH
+ Start End Missed
cleavage
Sequence CDR
1304.7103 19 30 1 (R)VTITCRASQGIR(N) 1
2108.1035 25 42 1 (R)ASQGIRNYLAWYQQKPGK(A) 1
1791.954 31 45 1 (R)NYLAWYQQKPGKAPK(L) 1
1495.7692 31 42 0 (R)NYLAWYQQKPGK(A) 1
1972.1225 43 61 1 (K)APKLLIYAASTLQSGVPSR(F) 2
1675.9377 46 61 0 (K)LLIYAASTLQSGVPSR(F) 2
3563.6383 62 93 1 (R)FSGSGSGTDFTLTISSLQPED
VATYYCQRYNR(A)
3
3130.4309 62 90 0 (R)FSGSGSGTDFTLTISSLQPEDVA
TYYCQR(Y)
3
1502.7386 91 103 1 (R)YNRAPYTFGQGTK(V) 3
1538.8213 94 107 1 (R)APYTFGQGTKVEIK(R) 3
1069.5313 94 103 0 (R)APYTFGQGTK(V) 3
Table 1 Identified CDR peptide
sequences of the light chain
of adalimumab
Mutations from the germline
sequence are bold and under-
lined in the sequence
Table 2 Detected CDR peptide sequences of an in-solution digest of adalimumab in a background of a commercial IgG pool (Nanogam)
MH
+ Start End Missed cleavage Sequence CDR ratio total
IgG/adalimumab
absolute spiked
amount (fmol)
2108.1035 25 42 1 (R)ASQGIRNYLAWYQQKPGK(A) 1 0.001 11
1495.7692 31 42 0 (R)NYLAWYQQKPGK(A) 1 0.00001 0.11
1675.9377 46 61 0 (K)LLIYAASTLQSGVPSR(F) 2 N.A.* N.A.*
1069.5313 94 103 0 (R)APYTFGQGTK(V) 3 0.0001 1.1
*Sequence is not specific for the adalimumab antibody and is also present in commercial IgG pool. N.A. = not applicable
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resolution by Orbitrap MS. For adalimumab, we focused
our analyses on three peptides of the CDRs of the light
chain. All three peptides at both concentrations could be
identified using Mascot database search. The mass spectra
of the three specific peptides of the CDRs of the light chain
were de novo sequenced using the computer program
Peaks. For the three peptides, two could be correctly
identified based on both fragmentation spectra. As an
example two fragmentation spectra of one peptide are
displayed (CID and HCD) in Fig. 5. The confidence score
for the HCD results were higher, and the difference in
scoring between the correct proposal and other incorrect
proposals was larger compared to the CID approach. The
quality of the HCD fragmentation spectra performed on a
10 fmol/μl concentration was not sufficient to obtain a
correct de novo sequence; at a 100 fmol/μl concentration a
complete de novo sequence could be obtained. In contrast,
the CID spectra for both concentrations were comparable in
quality and did not result in different de novo results.
Affinity-purification
We used a dot-blot to test the binding between mouse anti-
DNP antibodies and DNP-BSA, visualized by a secondary
alkaline phosphatase-labeled antibody. Dot-blots were
incubated with 0.1 and 0.01 μg of anti-DNP antibody
spiked into human IgG as well as human IgG alone as a
negative control. In addition, we used three amounts of
anti-DNP in buffer (0.1, 0.01 and 0.001 μg). Densitometry
of the scanned image of the dot-blot showed that the
binding of anti-DNP is related to concentration (Fig. 6). For
the spiked samples, the observed color intensity is
comparable to the spots incubated with anti-DNP alone.
Negative controls using anti-DNP show a negligible
background, comparable to that of a negative control
containing BSA.
For preparative extraction of anti-DNP antibodies from
serum IgG and subsequent analyses by mass spectrometry
we used magnetic beads coupled with BSA-DNP. Three
amounts of anti-DNP (0.5, 1 and 2 μg) were used, both in
buffer and spiked in IgG purified from human serum
(20 μg). We used the most abundant specific peptides of the
mouse monoclonal anti-DNP to monitor the purification
procedure. As an example, the intensities of one peptide of
the constant region (VNSAAFPAPIEK) is plotted against
the amount of anti-DNP used (see Fig. 7). The intensity of
this peptide increases linearly with the amount of used anti-
DNP antibodies. This linear correlation is also observed
when the peptide is spiked into human IgG (see Fig. 7).
Unspecific binding is negligible on uncoated beads and
beads coated with BSA-DNP incubated in human IgG. The
observed intensities of peptides of human IgG and BSA are
at least 100 times lower than specific signals observed for
affinity purified anti-DNP antibody at the lowest concen-
trations measured. The intensities of IgG peptides measured
on the beads by the fluorescence-based Luminex approach
correspond to the mass spectrometry measurements i.e.
similar linear curves are observed. In addition, we measured
anti-DNP spiked into IgG without subsequent affinity
purification. The amount of sample that could be loaded
is limited by the loading capacity of the column. In samples
with anti-DNP antibody in a background of 20 μgo f
human IgG, the signal intensity of the mouse IgG decreased
an order of magnitude, in part because of the amount of
material that could be loaded on the system (see Fig. 7).
Therefore, we also analyzed the same amounts of anti-DNP
antibody in only 2 μg of human IgG. Using these samples
we could inject the same amounts of the spiked anti-DNP
samples. For the highest concentration (2 μg of anti-DNP)
we observed similar intensities as for the affinity-purified
samples. The lower concentrations (0.5 and 1 μg) showed a
decrease in intensity (20-30%) in comparison with the
affinity-purified samples. The decrease in intensity is
probably related to ion suppression of the signal in the
mass spectrometer caused by the presence of relative high
concentrations of human IgG peptides.
Discussion
We determined the sensitivity for the detection and
identification of specific CDR peptides in complex IgG
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Fig. 2 Dilution series of adalimumab in a pooled IgG sample. Log10
of the intensities for the CDR1 peptide (R)NYLAWYQQKPGK(A) of
the light chain of adalimumab are plotted against the Log10 of the
spiked ratios of adalimumab in pooled IgG. The dashed horizontal line
indicates the background intensity. This intensity corresponds to the
signal that is observed at the position of the peptide in non-spiked
samples. This plot shows that the correlation between the peptide
intensity and concentration of spiked adalimumab is linear over at
least three orders of magnitude
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showed that specific CDR peptides of a spiked antibody
could be detected at sub-femtomole amounts and in
concentrations that are 5 orders of magnitude lower than
the total IgG concentration in serum.
The detectable concentrations of CDR peptides of
adalimumab when spiked into Nanogam IgG pool were at
least a factor 10 lower than after spiking into IgG purified
from donor sera by Melon Gel. A possible explanation for
this is that the Melon Gel purified samples are more
contaminated than the commercial IgG pool. These con-
taminations could be observed on gel, where in addition to
the light and heavy chain other bands are visible (see
Fig. 4). One of the major contaminants revealed by nanoLC
Orbitrap analyses was serotransferrin. By means of the UV
signal of the liquid chromatography test runs we prevented
overloading of the column and ensured the best possible
separation of the peptides during the Orbitrap measurement.
Fig. 4 SDS-PAGE loaded with Melon gel purified IgG from four
serum samples (loaded amount is equivalent to 0.5 μl of serum) and
5 μg of the commercial IgG pool (Nanogam). Lane 1 contains a
protein marker, lanes 2-5 Melon gel purified IgG and lane 6 contains
5 μg of the commercial IgG pool. Based on gel densitometry, the IgG
purified with Melon Gel is more contaminated with serum proteins
(50-60%) than the commercial IgG pool (10-15%). The recovery of
the IgG was about 100% for the Melon Gel purification
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Fig. 3 Chromatographic traces of a nanogam sample spiked with
0.1% Adalimumab. Panel A shows the base peak intensity chromato-
graph, panel B shows the extracted ion chromatogram of CDR1
peptide (R)NYLAWYQQKPGK(A) and panel C the extracted ion
chromatogram of a peptide of the constant region that is eluting at the
same retention time as the CDR peptide of interest
1088 L.J.M. Dekker et al.Contaminations in the samples result in less IgG being
loaded onto the column for the Orbitrap analyses, which
will decrease the sensitivity. In addition, the contaminations
will also affect the detection and could result in ion-
suppression of the MS signals if peptides of contaminants
co-elute with peptides of IgG. These possible factors might
explain the improved sensitivity that is observed when the
SDS-PAGE step is included for the spiked Melon Gel IgG
samples. Using this step, the impurities in the IgG sample
were considerably reduced. In addition, the light and heavy
0.1 µg DNP-BSA + + + +
1 µg BSA - - -+
Anti-DNP (µg) 0.0001 0.001 0.01 -
0.1µg DNP-BSA + + +
1 µg IgG + + +
Anti-DNP (µg) 0.001 0.01
Fig. 6 Dot-blots of DNP-BSA incubated with purified IgG spiked
with monoclonal anti-DNP. These dot-blots show that the intensity of
the signal increases with the amount of spotted anti-DNP. The
intensities of anti-DNP spiked into IgG are comparable to those of
pure anti-DNP. The background signal of IgG alone is less than the
signal observed for 0.001 μg of anti-DNP antibody. For the three
replicates per measurement an average CV of 4% for the various
concentrations was obtained by densitometry
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Fig. 5 Annotated MS/MS spectra of mass 748.38822
2+ (R)NYLA-
WYQQKPGK(A) obtained by CID and HCD fragmentation. The
signal to noise in the CID spectrum is much higher compared to the
HCD spectrum. Because of the higher mass accuracy in the HCD
spectra and the possibility of detecting the lower mass fragments the
confidence score for most of the amino acid sequence has increased in
HCD. Combined interpretation of both spectra results in de novo
sequences with a higher confidence compared to HCD spectra or CID
spectra alone
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decreases the complexity of the sample and therefore
increases the expected number of identifications.
The success of identifying a peptide based on de novo
sequencing depends on spectra quality and mass accuracy.
A combination of a CID spectrum in the LTQ of the
Orbitrap and HCD spectrum measured in the Orbitrap gives
complementary information which benefited peptide iden-
tification as can be seen in Fig. 4. We have shown that even
at low femtomol levels, database interpretable CID spectra
can still be obtained. HCD is a more energetic fragmenta-
tion which results in additional fragments. Using this
method, the low mass region can be measured as well
because it does not suffer from the one third mass cut-off as
is the case in iontrap CID fragmentation. In addition, the
mass accuracy in HCD is better for the fragments generated
than in CID which helps to confirm the predicted sequence
considerably. For the peptides of interest, we typically
observed that, on average, a concentration of 100 femtomol
of peptide is required to obtain de novo interpretable HCD
fragmentation spectra. When acquiring HCD spectra,
standard CID spectra can be obtained without additional
analysis time because it is performed in parallel to HCD
fragmentation and spectra acquisition. This means that for
low intensity signals with a poor HCD spectrum, the more
sensitive CID is still available. For two out of three CDR
peptides of the light chain of adalimumab the top scoring
proposed sequence by the de novo sequencing software was
completely correct. This is in agreement with data from a
larger test set in which a comparison of a database search
and de novo sequencing results is performed. In this test,
the same sequences were obtained for the database search
and the de novo sequencing in 50-70% of the cases
depending on the settings used (data not shown).
This percentage can be further increased when in
addition to this method ETD fragmentation is used.
Another alternative to improve the coverage of CDRs is
to use different enzymes [17–20] and to obtain peptides that
are cut at different positions which can potentially fragment
or ionize better or complement the sequencing information
obtained of tryptic peptides.
We have shown that it is possible to detect specific CDR
peptides at attomole levels at spiked concentrations which
were 5 orders of magnitude lower than the concentration of
the IgG serum background. This method can be further
improved by including additional and more efficient
separation steps. We demonstrated in this study that an
affinity-purification is a useful step to enrich antibodies
specific for an antigen. This purification results in an
increase of sensitivity of at least one order of magnitude for
the mass spectrometry analyses comparing enriched to not
enriched samples. An advantage of this approach is that the
total column capacity can be used for the peptides of
specific IgGs resulting in an increased sensitivity. In
addition, the amount of suppression is reduced as can be
observed in Fig. 7. Using this purification method,
relatively large quantities of specific IgG can be obtained:
from only 100 μl of serum several μg’s of specific IgG can
probably be harvested. We have demonstrated that a μgo f
affinity-purified IgG is sufficient for the identification of
specific CDRs by our approach. This approach shows that
specific antigens with unknown identity gives possibilities
to identify specific CDRs. It may also be possible to extend
this method to the affinity enrichment of antibodies against
a tissue or protein mixture containing antigens that have not
been fully purified, or antigens in such a mixture that are
still unidentified.
Conclusions
We have shown that relatively high sensitivities for the
detection of specific CDR peptides can be obtained in
serum IgG fractions. If this approach is applicable to detect
CDR peptides of disease related antibodies in patients
samples has to be further investigated. However, based on
our own data [13], we expect that 1-3 % of total IgG can
have affinity to an antigen. In addition, a polyclonal
antibody response against a protein consists of approxi-
mately 100 B-cell clones [21] (these clones can undergo
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Fig. 7 Intensity of a mouse constant region peptide as a function of
the amount of mouse anti-DNP used. The blue diamonds show the
intensities of the affinity purified anti-DNP in buffer, the red squares
show the intensities of affinity purified anti-DNP spiked in 20 μgo f
IgG, the green triangles show the intensities of anti-DNP spiked in
two μg of IgG without affinity purification, the purple circles show the
intensities of anti-DNP spiked in twenty μg of IgG without affinity
purification. The intensities of anti-DNP constant region peptide
VNSAAFPAPIEK in buffer and spiked in human IgG purified on
magnetic beads show similar intensities and both are linearly
correlated (R
2=0.99). When no magnetic bead purification is applied,
the addition of 2 μg human IgG results in a suppression of the peptide
signal at lower concentrations of anti-DNP. Spiking anti-DNP into
20 μg human IgG results in a much more pronounced decrease in
intensity
1090 L.J.M. Dekker et al.further mutations during maturation). Therefore a particular
antibody would be present at a fraction of at most 0.01 % of
total IgG depending on the intensity of the immunological
reaction against the antigen and diversification in the B cell
clones. The expectation that CDRs of specific antibodies at
these concentrations can be detected and identified seems to
be realistic based on the data presented and previously
published data [12, 13]. This would make it possible to use
the described technique for an antibody-based biomarker
approach. In addition, we have shown that if the antigen is
known and is available in a purified form, an immune
affinity capturing can be used to further increase the
sensitivity of the method. For many autoimmune diseases
the antigen is known and can be used for enrichment of
specific autoantibodies to study the antibody production in
patients in more detail.
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